William Blair analyst Tim Lugo has maintained their bullish stance on CRSP stock, giving a Buy rating on February 15.
Tim Lugo has given his Buy rating due to a combination of factors surrounding Crispr Therapeutics AG’s recent progress and future prospects. The approval of Casgevy in multiple regions including the U.S., EU, Great Britain, KSA, and Bahrain, with pending reviews in Switzerland and a forthcoming submission in Canada, showcases the company’s growing global presence. Moreover, the successful launch efforts by partner Vertex, such as activating treatment centers and securing a significant payer agreement, enhance the market penetration and accessibility of Casgevy, further underpinning Lugo’s positive outlook.
In addition, Crispr Therapeutics AG’s pipeline offers a plethora of catalysts that promise to sustain the company’s momentum. The development of next-generation CAR-T candidates CTX112 and CTX131, with planned Phase I studies, signifies the company’s commitment to expanding its therapeutic reach. The ongoing Phase I trials for in vivo gene editing programs CTX310 and CTX320 also indicate potential breakthroughs in the treatment of genetic conditions. These forthcoming developments, alongside the anticipated nomination of additional in vivo programs, provide a robust basis for Lugo’s Buy recommendation, reflecting confidence in the company’s innovative trajectory and anticipated growth.
In another report released on February 15, Mizuho Securities also assigned a Buy rating to the stock with a $82.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Crispr Therapeutics AG (CRSP) Company Description:
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
- Crispr Therapeutics initiated with a Peer Perform at Wolfe Research
- Cathie Wood’s ARK Investment bought 280K shares of Crispr Therapeutics today
- Crispr Therapeutics Secures Funding Through Share Issuance
